GSK US FDA Approval

Yesterday, October 23, 2025, GSK plc (GSK) announced the United States Food and Drug Administration (FDA) has approved Blenrep in combination with bortezomib and dexamethasone (BVd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor (PI